Radiochemotherapy in small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1379-1387

  Kepka, Lucyna ^a   Sprawka, Arkadiusz ^a   Casas, Francesc ^b   Abdel Wahab, Sherif ^c   Agarwal, Jai Prakash ^d   Jeremic, Branislav ^e  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b HOSPITAL CLÍNIC   (Spain)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d TATA MEMORIAL HOSPITAL   (India)

^e Institute of Pulmonary Diseases   (Serbia)

Author keywords

Chemotherapy; Prophylactic cranial irradiation; Radiochemotherapy; Radiotherapy; Randomized study; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; PLATINUM COMPLEX; VINCRISTINE;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEASIBILITY STUDY; HUMAN; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 70350608199     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.122     Document Type: Review

References (71)

1. Micke P, Faldum A, Metz T et al. Staging small cell lung cancer: Veterans Administration Lung study group versus International Association for the study of Lung Cancer - what limits limited disease? Lung Cancer 37(3), 271-276 (2002). (Pubitemid 35286725)
2. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 24(28), 4539-4544 (2008). •• Analysis of changing epidemiology of small-cell lung cancer (SCLC) with an analysis of modest improvement of survival from the epidemiologist's point of view. (Pubitemid 46630948)
3. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J. Clin. Oncol. 10(6), 890-895 (1992).
4. Pignon JP, Ariagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N. Engl. J. Med. 327(23), 1618-1624 (1992). • Important meta-analysis demonstrating an effect of thoracic irradiation on survival in limited-disease (LD)-SCLC.
5. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission: a meta-analysis of individual data from 987 patients. N. Engl. J. Med. 341(7), 476-484 (1999). • Important meta-analysis demonstrating an effect of the prophylactic cranial irradiation use on survival.
6. Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N. Engl. J. Med. 357(7), 664-672 (2007). (Pubitemid 47267236)
7. Bleehen NM, Bunn PA, Cox JD et al. Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat. Rep. 67(1), 11-19 (1983).
8. Perez CA, Einhorn L, Oldham RK et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J. Clin. Oncol. 2(11), 1200-1208 (1984).
9. Bunn PA, Lichter AS, Makuch RW et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann. Intern. Med. 106(5), 655-662 (1987).
10. Perry MC, Eaton WL, Propert KJ et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N. Engl. J. Med. 316(15), 912-918 (1987).
11. Sundstrom S, Bremnes RM, Kaasa S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized Phase III trial with 5 years' follow-up. J. Clin. Oncol. 20(24), 4665-4672 (2002). (Pubitemid 36025283)
12. Mascaux C, Paesmans M, Berghmans T et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30(1), 23-36 (2000).
13. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br. J. Cancer 83(1), 8-15 (2000).
14. Amarasena IU, Walters JA, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small-cell lung cancer. Cochrane Database Syst. Rev. 8(4), CD006849 (2008).
15. Skarlos DV, Samanta E, Kosmidis P et al. Randomised comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann. Oncol. 5(7), 601-607 (1994).
16. Ettinger DS, Berkey BA, Abrams RA et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 Phase II study. J. Clin. Oncol. 23(22), 4991-4998 (2005).
17. Baas P, Belderbos JSA, Senan S et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved field radiotherapy in limited stage small cell lung cancer: a Dutch multi-center Phase II study. Br. J. Cancer 94(5), 625-630 (2006). (Pubitemid 43361891)
18. Mavroudis D, Papadakis E, Veslemes M et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first line treatment in patients with small-cell lung cancer. Ann. Oncol. 12(4), 463-470 (2001). (Pubitemid 32472099)
19. Niell HB, Herndon JE 2nd, Miller AA et al. Randomised Phase III Intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small cell lung cancer. J. Clin. Oncol. 23(16), 3752-3759 (2005).
20. Castellano D, Bartolome A, Font A et al. Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC). ASCO Annual Meeting Proceedings. Part I. J. Clin. Oncol. 24(Suppl.), 7084 (2006).
21. Jeong HC, Lee SY, Lee SY et al. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer 53(3), 361-366 (2006).
22. Klautke G, Fahndrich S, Semrau S, Buscher C, Virchov C, Fietkau R. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a Phase I study. Lung Cancer 53(3), 183-188 (2006). (Pubitemid 43994232)
23. Fukuda M, Soda H, Fukuda M et al. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced non-small cell lung cancer: a multiinstitutional Phase 2 study. Cancer 110(3), 606-613 (2007).
24. Sohn JH, Moon YW, Lee CG et al. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. Cancer 109(9), 1845-1850 (2007).
25. De Jong WK, de Jonge MJ, van der Leestc AH, van Meerbeck JP, Groena HJ. Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a Phase I study. Lung Cancer 61(1), 123-128 (2008).
26. Murray N, Coy P, Pater JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: the National Cancer Institute of Canada Clinical Trials group. J. Clin. Oncol. 11(2), 336-344 (1993).
27. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J. Clin. Oncol. 15(3), 893-900 (1997). (Pubitemid 27106269)
28. Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer group. J. Clin. Oncol. 14(9), 3030-3037 (1997). (Pubitemid 27377494)
29. Gregor A, Drings P, Burghouts J et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative group study. J. Clin. Oncol. 15(8), 2840-2849 (1997). (Pubitemid 27330011)
30. Perry MC, Herndon JE 3rd, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B study 8083. J. Clin. Oncol. 16(7), 2466-2467 (1998).
31. Skarlos DV, Samantas E, Briassoulis E et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized Phase II study of the Hellenic Cooperative Oncology group (HeCOG). Ann. Oncol. 12(9), 1231-1238 (2001). (Pubitemid 32994750)
32. Takada M, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J. Clin. Oncol. 20(14), 3054-3060 (2002). (Pubitemid 34791094)
33. Spiro SG, James LE, Rudd RM et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J. Clin. Oncol. 24(24), 3823-3830 (2006).
34. Turrisi AT 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340(4), 265-271 (1999).
35. Fried DB, Morris DE, Poole C et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J. Clin. Oncol. 22(23), 4837-4845 (2004). (Pubitemid 41185097)
36. Pijls-Johannesma MCG, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage cell lung cancer. Cochrane Database Syst. Rev. 4, CD004700 (2004).
37. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann. Oncol. 17(4), 543-552 (2006). •• Meta-analysis showing advantage of early initiation of radiotherapy in LD-SCLC.
38. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J. Clin. Oncol. 24(7), 1057-1063 (2006). (Pubitemid 46638802)
39. Jeremic B. Timing of concurrent radiotherapy and chemotherapy in limited-disease small-cell lung cancer: "Meta-analysis of meta-analyses". Int. J. Radiat. Oncol. Biol. Phys. 64(4), 981-982 (2006).
40. Coy P, Hodson I, Payne D et al. The effect of dose of thoracic irradiation on recurrence in patients with limited-stage small-cell lung cancer. Initial results of a Canadian multicentre randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 14(2), 219-226 (1988). (Pubitemid 18042180)
41. Schild SE, Bonner JA, Shanahan TG et al. Long-term results of a Phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited stage small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 943-951 (2004).
42. Choi NC, Herndon JE, Rosenman J et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated- accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J. Clin. Oncol. 16(11), 3528-3536 (1998). (Pubitemid 28506764)
43. Bogart JA, Herndon JE 2nd, Lyss AP et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int. J. Radiat. Oncol. Biol. Phys. 59(2), 460-468 (2004).
44. Miller AA, Wang XF, Bogart JA et al. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J. Thorac. Oncol. 2, 645-651 (2007).
45. Bogart JA. Rationale for Phase III trials of thoracic radiation therapy doses in limited-stage small-cell lung cancer. Clin. Lung Cancer 9(4), 202-205 (2008).
46. Komaki R, Swann RS, Ettinger DS et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: report of Radiation Therapy Oncology group (RTOG) protocol 97-12. Int. J. Radiat. Oncol. Biol. Phys. 62(2), 342-350 (2005). (Pubitemid 40704448)
47. Komaki R, Moughan J, Ettinger DS et al. Toxicities in a Phase II study of accelerated high dose thoracic radiation therapy (TRT) with concurrent chemotherapy for limited small cell lung cancer (LSCLC) (RTOG 0239). ASCO Annual Meeting Proceedings. Part I. J. Clin. Oncol. 25(Suppl.), 7717 (2007).
48. Yee D, Halperin R, Hanson J et al. Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 65(2), 466-473 (2006).
49. Videtic GM, Truong PT, Dar AR, Yu EW, Stitt LW. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 57(3), 709-716 (2003).
50. Kies MS, Mira JG, Crowley JJ et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group study. J. Clin. Oncol. 5(4) 592-600 (1987).
51. Mira JG, Livingston RB. Evaluation and radiotherapy implications of chest relapse patterns in small cell lung carcinoma treated with radiotherapy- chemotherapy: study of 34 cases and review of the literature. Cancer 46(12), 2557-2565 (1980).
52. Liengswangwong V, Bonner JA, Shaw EG et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J. Clin. Oncol. 12(3), 496-502 (1994). (Pubitemid 24079890)
53. De Ruysscher D, Bremer RH, Koppe F et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a Phase II trial. Radiother. Oncol. 80(3), 307-312 (2006). (Pubitemid 44397204)
54. Videtic GMM, Belderbos JSA, Kong F-M (Spring), Kepka L, Martel MK, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants meeting on elective nodal irradiation in lung cancer: small cell lung cancer (SCLC). Int. J. Radiat. Oncol. Biol. Phys. 72(2) 327-334 (2008). • A detailed and critical overview of problems of elective nodal irradiation in LD-SCLC.
55. Arriagada R, Le Chevalier T, Borie F et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl Cancer Inst. 87(3), 183-190 (1995).
56. Aroney RS, Aisner J, Wesley MN et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat. Rep. 67(7-8), 675-682 (1983).
57. Gregor A, Cull A, Stephens RJ et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small-cell lung cancer: results of a multicenter randomized trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC) Eur. J. Cancer 33(11), 1752-1758 (1997).
58. Ohonoshi T, Ueoka H, Kawahara S et al. Comparative study of prophylactic cranial irradiation in patients with small-cell lung cancer achieving a complete response: a long-term follow-up results. Lung Cancer 10(1-2), 47-54 (1993). (Pubitemid 23341209)
59. Laplanche A, Monner I, Santos-Miranda JA et al. Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer incomplete remission. Lung Cancer 21(3), 193-201 (1998). (Pubitemid 28491367)
60. Le Pechoux C, Dunant A, Senan S et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomized clinical trial. Lancet Oncol. 10(5), 467-474 (2009).
61. Lee JJ, Bekele BN, Zhou X, Cantor SB, Komaki R, Lee JS. Decision analysis for prophylactic cranial irradiation for patients with small cell lung cancer. J. Clin. Oncol. 24(22), 3597-3603 (2006). (Pubitemid 46630532)
62. Suwinski R, Lee SP, Withers HR. Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 40(4), 797-806 (1998). (Pubitemid 28150796)
63. Pujol JL, Daures JP, Riviere A et al. Etoposide plus cisplatin with or without the combination of 4-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter Phase III randomized study. J. Natl Cancer Inst. 93(4), 300-308 (2001). (Pubitemid 32219817)
64. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with cisplatin plus etoposide/cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85-91 (2002). (Pubitemid 34438898)
65. Hermes A, Bergman B, Bremnes R et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized Phase III trial. J. Clin. Oncol. 26(26), 4261-4267 (2008).
66. Hanna N, Bunn PA Jr, Langer C et al. Randomized Phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive stage disease small-cell lung cancer. J. Clin. Oncol. 24(13), 2038-2043 (2006). (Pubitemid 46622112)
67. Lara PN, Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27(15), 2530-2535 (2009).
68. Jeremic B, Shibamoto Y, Nikolic N et al. The role of radiation therapy in the combined modality treatment of patients with extensive disease small cell lung cancer: a randomised trial. J. Clin. Oncol. 17(7), 2092-2099 (1999). (Pubitemid 29318840)
69. Bayman NA, Sheikh H, Kularatne B et al. Radiotherapy for small-lung cancer - where are we heading? Lung Cancer 63(3), 307-314 (2009). •• An overview of the radiotherapy use in SCLC from the contemporary perspective.
70. Slotman BJ, Mauer ME, Bottomley A et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer groups. J. Clin. Oncol. 27(1), 78-84 (2009).
71. Kepka L, Casas F, Perin B et al. Radiochemotherapy for lung cancer in developing countries. Clin. Oncol. (R. Coll. Radiol.) 21(7), 536-542 (2009).